Early changes of hepatitis B virus quasispecies during lamivudine treatment and the correlation with antiviral efficacy

被引:97
|
作者
Chen, Li [2 ]
Zhang, Qian [1 ]
Yu, De-min [2 ]
Wan, Mo-bin [1 ]
Zhang, Xin-xin [2 ]
机构
[1] Second Mil Med Univ, Changhai Hosp, Dept Infect Dis, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Dept Infect Dis, Ruijin Hosp, Shanghai 200030, Peoples R China
关键词
Hepatitis B virus; Treatment outcome; Lamivudine; Genetic heterogeneity; Evolution; INTERFERON THERAPY; VIRAL DYNAMICS; COMBINATION; RESISTANCE; EVOLUTION; SELECTION; PREDICT; REGION; SERVER;
D O I
10.1016/j.jhep.2008.12.018
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims:To investigate dynamic changes of hepatitis B virus (HBV) quasispecies within the reverse transcriptase (RT) region during the early stage of lamivudine treatment and the correlation with antiviral efficacy. Methods: Twenty-five chronic hepatitis B patients received lamivudine treatment for 48 weeks. Fourteen patients responded to lamivudine, while eleven patients were non-responders. HBV DNA was extracted from serum samples at baseline and week 4. The RT region of HBV was amplified, then cloned and sequenced. Quasispecies complexity and diversity within the RT region were analyzed at baseline and week 4, and viral nucleotide substitution rates during the first 4 weeks were calculated. Results: The quasispecies complexity and diversity were not different between responders and non-responders at baseline (p > 0.05). However, the quasispecies complexity and diversity of responders were significantly lower than those of non-responders at week 4 (p < 0.01). Furthermore, the viral nucleotide substitution rate of responders was significantly higher than that of non-responders (p < 0.05). Conclusions:The dynamic changes of HBV quasispecies within the RT region showed distinct patterns between responders and non-responders during early stage of lamivudine treatment. The dynamic changes of quasispecies complexity and diversity during the first 4 weeks were correlated with lamivudine antiviral efficacy and antiviral resistance. Crown copyright (c) 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:895 / 905
页数:11
相关论文
共 50 条
  • [21] Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis
    Ooga, H
    Suzuki, F
    Tsubota, A
    Arase, Y
    Suzuki, Y
    Akuta, N
    Sezaki, H
    Hosaka, T
    Someya, T
    Kobayashi, M
    Saitoh, S
    Ikeda, K
    Kobayashi, M
    Matsuda, M
    Satoh, J
    Kumada, H
    JOURNAL OF GASTROENTEROLOGY, 2004, 39 (11) : 1078 - 1084
  • [22] Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance
    Yang, Hyo-Joon
    Lee, Jeong-Hoon
    Kim, Yoon Jun
    Yoon, Jung-Hwan
    Lee, Hyo-Suk
    JOURNAL OF MEDICAL VIROLOGY, 2012, 84 (03) : 424 - 430
  • [23] Efficacy of lamivudine in the treatment of children with chronic hepatitis B
    Figlerowicz, M
    Kowala-Piaskowska, A
    Filipowicz, M
    Bujnowska, A
    Mozer-Lisewska, I
    Sluzewski, W
    HEPATOLOGY RESEARCH, 2005, 31 (04) : 217 - 222
  • [24] Lamivudine treatment of decompensated hepatitis B virus-related cirrhosis
    Fu-Kui Zhang Liver Research Center
    Hepatobiliary&PancreaticDiseasesInternational, 2006, (01) : 10 - 15
  • [25] Utilization of transgenic mice replicating high levels of hepatitis B virus for antiviral evaluation of lamivudine
    Morrey, JD
    Bailey, KW
    Korba, BE
    Sidwell, RW
    ANTIVIRAL RESEARCH, 1999, 42 (02) : 97 - 108
  • [26] Antiviral treatment of chronic hepatitis B with lamivudine in pediatric renal transplantation
    Kranz, B
    Vester, U
    Bonzel, KE
    Paul, A
    Gerken, G
    Hoyer, PF
    PEDIATRIC TRANSPLANTATION, 2006, 10 (03) : 384 - 389
  • [27] Antiviral therapy for hepatitis B virus during second pregnancies
    Wakano, Yasuhiro
    Sugiura, Tokio
    Endo, Takeshi
    Ito, Koichi
    Suzuki, Mitsuyoshi
    Tajiri, Hitoshi
    Tanaka, Yasuhito
    Saitoh, Shinji
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2018, 44 (03) : 566 - 569
  • [28] Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan
    Suzuki, F
    Tsubota, A
    Arase, Y
    Suzuki, Y
    Akuta, N
    Hosaka, T
    Someya, T
    Kobayashi, M
    Saitoh, S
    Ikeda, K
    Kobayashi, M
    Matsuda, M
    Satoh, J
    Takagi, K
    Kumada, H
    INTERVIROLOGY, 2003, 46 (03) : 182 - 189
  • [29] Understanding Hepatitis B Virus Dynamics and the Antiviral Effect of Interferon Alpha Treatment in Humanized Chimeric Mice
    Reinharz, Vladimir
    Ishida, Yuji
    Tsuge, Masataka
    Durso-Cain, Karina
    Chung, Tje Lin
    Tateno, Chise
    Perelson, Alan S.
    Uprichard, Susan L.
    Chayama, Kazuaki
    Dahari, Harel
    JOURNAL OF VIROLOGY, 2021, 95 (14)
  • [30] Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections
    Koukoulioti, Eleni
    Brodzinski, Annika
    Mihm, Ulrike
    Sarrazin, Christoph
    Jung, Maria-Christina
    Schott, Eckart
    Fueloep, Balazs
    Schlosser, Beate
    Berg, Thomas
    van Boemmel, Florian
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 31 (07) : 845 - 852